依折麦布联合他汀对急性冠脉综合征行急诊介入患者残粒脂蛋白胆固醇及MACE影响的临床研究

目的：研究依折麦布联合他汀对急性冠脉综合征（ACS）行急诊介入术（PCI）后患者残粒样脂蛋白-胆固醇（RLP-C）水平及主要心血管不良事件（MACE）的影响。方法：选取入院诊断ACS并行急诊PCI患者共90人，术后常规冠心病二级预防用药，将其随机分为两组，对照组48例服用阿托伐他汀，研究组42例加用依折麦布治疗，检测治疗前后RLP-C水平，并通过定期随访获取患者治疗期间MACE及药物不良反应。结果：与对照组相比，研究组治疗后RLP-C水平明显下降（P<0.05），MACE发生率明显降低（P<0.05），药物不良反应没有增加。结论：依折麦布联合他汀治疗可以降低ACS行急诊PCI术后患者RLP-C水平，减少MACE，不良反应少，值得推广应用。

Clinical study of effect of ezetimibe combined with statins on residual lipoprotein cholesterol and MACE events in patients undergoing emergency intervention with acute coronary syndrome

AIM: To investigate the effect of ezetimibe combined with statins on residual lipoprotein-cholesterol (RLP-C) levels and major cardiovascular adverse events (MACE) in patients with acute coronary syndrome (ACS) after emergency intervention (PCI). METHODS: A total of 90 hospitalized patients with ACS and undergoing emergency PCI were randomly divided into two groups: 48 patients in the control group received atorvastatin, and 42 patients in the study group were additionally treated with ezetimibe. RLP-C level before and after treatment was detected. The occurrence of MACE events and adverse drug events during the treatment were obtained through regular follow-up. RESULTS: Compared with the control group, the level of RLP-C in the study group was significantly decreased (P<0.05), the incidence of MACE were significantly decreased (P<0.05), and adverse drug events were not increased. CONCLUSION: The combination therapy of ezedemibe and statins can reduce RLP-C level and MACE in ACS patients undergoing emergency PCI with less adverse reactions, which is worthy of promotion and application.